Puhe Biopharma

Executive Summary

Puhe Biopharma is a privately held Chinese biotechnology company founded in 2021, specializing in the development of innovative small-molecule therapeutics for oncology, immunology, and metabolic diseases. The company differentiates itself through an AI-integrated drug discovery platform that targets high-barrier mechanisms of action, including PROTACs, molecular glues, and synthetic lethality. Puhe's pipeline features next-generation kinase inhibitors and novel mechanism-based drugs, though specific programs are currently undisclosed. With 50-200 employees and a Phase 1 stage, the company is advancing its lead candidates toward clinical proof-of-concept, leveraging artificial intelligence to accelerate hit identification and optimization. As a private entity, Puhe has not disclosed its total funding or valuation, but its focus on cutting-edge modalities positions it within a competitive landscape of emerging Chinese biotechs.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 clinical data readout for lead PROTAC program40% success
• Q1 2027IND filing for molecular glue candidate60% success
• H2 2026Partnership or licensing deal for AI platform50% success